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Jacintha O’Sullivan4, Anthony O’Grady2, John Reynolds4, Seamus O’Reilly5, Gerald C. O’Sullivan1
and Sharon L. McKenna1*
Abstract
Background: Esophageal adenocarcinoma has the fastest growing incidence of any solid tumor in the Western
world. Prognosis remains poor with overall five-year survival rates under 25 %. Only a limited number of patients
benefit from chemotherapy and there are no biomarkers that can predict outcome. Previous studies have indicated
that induction of autophagy can influence various aspects of tumor cell biology, including chemosensitivity. The
objective of this study was to assess whether expression of the autophagy marker (LC3B) correlated with patient
outcome.
Methods: Esophageal adenocarcinoma tumor tissue from two independent sites, was examined retrospectively.
Tumors from 104 neoadjuvant naïve patients and 48 patients post neoadjuvant therapy were assembled into tissue
microarrays prior to immunohistochemical analysis. Kaplan-Meier survival curves and log-rank tests were used to
assess impact of LC3B expression on survival. Cox regression was used to examine association with clinical risk
factors.
Results: A distinct globular pattern of LC3B expression was found to be predictive of outcome in both patient
groups, irrespective of treatment (p < 0.001). Multivariate analysis found that this was a strong independent
predictor of poor prognosis (p < 0.001).
Conclusions: This distinctive staining pattern of LC3B represents a novel prognostic marker for resectable
esophageal adenocarcinoma.
Background
The last two decades have seen a significant increase in
the incidence of cancer of the oesophagus, with it be-
coming the seventh leading cause of cancer death in
the Western world [1]. There are two main histological
types of esophageal cancer; squamous cell carcinoma
and adenocarcinoma. The increasing incidence is predom-
inantly in esophageal adenocarcinoma. The principal treat-
ment regimen for localized esophageal adenocarcinoma in
Europe is pre-operative chemotherapy which is based on
cisplatin/5-fluorouracil (5-FU) or radio-chemotherapy,
followed by surgical resection [2]. Despite improvements
in diagnosis and treatment approaches, overall five-year
survival rates remain under 25 % [3]. Current
approaches cause considerable toxicity in the vast ma-
jority of patients and there are no pre-therapy markers
that could help to tailor treatment to those who would
benefit the most [4]. Pathological classifications of
tumor grade, differentiation, vascular invasion and
lymph node status are sub-optimal in predicting re-
sponse to neoadjuvant therapy [5]. Even following
complete pathological response, there is a significant
risk of disease recurrence and cancer-specific death fol-
lowing resection [6].
Basal and dynamic levels of autophagy are responsible
for the degradation of long lived or aggregated proteins
and damaged or superfluous organelles. Autophagy is ini-
tiated with the formation of a double-membraned phago-
phore that encapsulates cellular material and extends to
become a vesicle referred to as an autophagosome [7].
This then fuses with the lysosome, enabling degradation of
its contents [8]. Elongation of the phagophore membrane
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incorporates LC3II (microtubule-associated protein Light
Chain 3) which is considered the most specific marker for
autophagosome formation (and autophagy) [9].
Autophagy has been implicated in the pathogenesis of
cancer [10], but its exact role is still a matter of debate as
autophagy has been associated with both better and
poorer outcome [11, 12]. Autophagy may act as a survival
mechanism and energy reservoir for tumors subjected to
stressful conditions such as; hypoxia, nutrient deprivation,
metabolic stress and chemotherapy [13–16]. Inhibition of
autophagy has been reported to chemosensitize several
otherwise resistant cancer cells including chronic myeloid
leukemia [17], ovarian cancer [18], breast cancer [19], ma-
lignant glioma [20] and esophageal cancer [21]. Con-
versely, promotion of autophagy has been reported to be
important for anti-tumor immune responses following
chemotherapy [22, 23].
Several studies have evaluated the potential prognostic
value of autophagy markers, including Beclin 1 and LC3.
Most studies of LC3 have examined overall expression
levels and there is divergent opinion on its clinical signifi-
cance (see later/discussion). In addition, other studies have
reported distinct distribution patterns of the autophagy
marker LC3 in several cancers. In particular, staining of
LC3A stone-like structures (SLS) has been associated with
tumor progression and a poor prognosis in epithelial tu-
mors [24]. In gastric cancers, these structures were associ-
ated with an increased rate of recurrence after resection
[25]. The significance of LC3 staining patterns in esopha-
geal adenocarcinoma is still unknown. In this study, we
evaluated the expression of the autophagy marker LC3B
in two different groups of esophageal adenocarcinoma pa-
tients; Group 1 (neoadjuvant-naïve) and Group 2 (received
pre-operative neoadjuvant therapy). We examined the
relationship between LC3B expression and overall survival
of patients in both groups.
Methods
Patients
Patients who were diagnosed with esophageal adenocar-
cinoma were identified retrospectively from the pathology
department records at the Mercy University Hospital,
Cork (n = 50) and Saint James’s Hospital, Dublin, Ireland
(n = 102). Ethical approval for this study was obtained
from the Clinical Research Ethics Committee of the Cork
Teaching Hospitals and for the St. James site, the Ethics
Committee at the Adelaide and Meath Hospital, Tallaght,
Dublin. All of the patients were diagnosed and treated at
the Mercy University Hospital, Cork or St James’s Hos-
pital, Dublin, between 2000 and 2006. One hundred and
four patients did not receive neoadjuvant therapy (Group
1) while 48 patients received neoadjuvant therapy (Group
2). All neoadjuvant patients in Cork and Dublin had pre-
operative chemo-radiotherapy, followed by surgical
resection. Neoadjuvant treatment is indicated for patients
who are candidates for curative surgical resection. Chemo-
therapy is based on cisplatin/5-fluorouracil (5-FU). Clinical
and histopathological data from both sites is shown in
Additional file 1: Table S1. Archival formalin fixed, paraf-
fin embedded tumor blocks and corresponding normal
esophageal mucosa, and lymph node metastasis (if avail-
able), were also collected. All surgical esophageal adeno-
carcinoma tumors were assembled into tissue microarrays
(TMAs) prior to immunohistochemical (IHC) analysis.
Cell culture
Established human esophageal cancer cell lines OE19,
OE21 and OE33, were obtained from the ECACC
(European Collection of Cell Cultures, 96071721, 96062201
and 96070808). KYSE450 cells were from DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH).
OE21 and KYSE450 are of squamous origin and OE19
and OE33 are adenocarcinoma. OE19, OE21 and OE33
cell lines were maintained in RPMI 1640 medium,
KYSE450 cells were maintained in 50:50 RPMI 1640:F-12
HAMS medium, all supplemented with 1 % penicillin/
streptomycin, 10 % (v/v) fetal calf serum (Gibco, 21875–
034, 15070–063, 10270) at 37 °C, 5 % CO2.
Embedding cell lines into paraffin
Cells (~2.0 × 107) were collected, washed with PBS and
re-suspended in 1 ml of warm 1 % agarose/10 % neutral
buffered formalin. The pellets were then processed by
standard tissue processing technique and embedded into a
paraffin block.
Analysis of recombinant proteins by western blotting
Human recombinant microtubule-associated proteins
1A/1B light chain 3A and 3B were purchased from Enzo
Life Sciences (BML-UW1145 and BML-UW1155, re-
spectively) and run on NuPAGE 4–12 % Bis-Tris gels
(Invitrogen NP0322) and probed with either the Abgent
anti-LC3 antibody (Abgent AP1802a) or with the MBL
anti-LC3A & B antibody (MBL PD014) to confirm integ-
rity of protein. Proteins were visualized using relevant
IR-Dye conjugated secondary antibodies (Li-Cor 926–
32211) on the Odyssey IR imaging system (Li-Cor, UK).
Quantified data is presented as integrated intensity.
Immunofluorescence staining
Cytospins were fixed in 4 % paraformaldehyde (PFA) for
20 min and washed with PBS. Permeabilization was car-
ried out with 0.005 % saponin/PBS for active caspase-3
and 0.2 % Triton X for LC3B. All sections were blocked
with 5 % BSA/PBS for 1 h at room temperature. Primary
antibodies [LC3B (Abgent, AP1802a) and active caspase-3
(Cell Signaling 9664)] were incubated overnight at 4 °C.
After incubation with alexa fluor 488 (Invitrogen, Ireland)
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slides were mounted with Prolong Gold antifade reagent
with DAPI (Molecular Probes, P36935). All slides were
viewed using a DP70 Olympus digital microscope camera
at 40×. Images were captured with Olympus DP-Soft823
version 3.2 acquisition software.
Immunohistochemistry staining
Slides were de-waxed and antigen retrieval was performed
in 0.1 M citrate buffer (pH 6.0) with microwave heating for
20 min. Endogenous peroxidase was blocked with peroxid-
ase block (EnVision + System-HRP (DAP), Dako) for 5 min,
at room temperature, and 5 % BSA in PBS was added to
the slides for 1 h to reduce nonspecific binding. Slides were
incubated overnight at 4 °C with Atg8b (LC3B) antibody
(Abgent AP1802a) diluted 1:100 in 5 % BSA/PBS. After
washing in PBS, sections were incubated with polymer-
HRP labelled secondary antibody (EnVision + System-HRP
(DAP), Dako) at 37 °C for 45 min. A drop of DAP-
chromagen was added and sections were counterstained
with hematoxylin. In negative control slides, PBS replaced
the primary antibody and positive staining was absent.
Quantification of immunohistochemistry staining
Three distinct patterns of LC3B immunohistochemical
staining were identified and enumerated in each tissue
core (subsequently referred to as sections); (i) cytoplas-
mic, (ii) crescent or ring-like structures and (iii) large
globule like structures.
These three patterns of LC3B staining were assigned
scores as follows: The proportion of neoplastic cells with
a cytoplasmic pattern of reactivity ranged from 5–90 %
per section at 100× magnification (median, 40 %). The
60th percentile was used to classify tumours into negative
(< 60 % percentile) and positive (≥ 60 % percentile). Tumor
sections were considered positive if 50 % or more of the
viable tumor cells showed strong cytoplasmic staining.
The number of crescent or ring-like structure and
globular structures were enumerated in each section at a
magnification of 400× and expressed as the mean of all
counts. The number of crescent or ring-like structures
and globular structures ranged from one to six (80th
percentile was four) per section. The tumors were subse-
quently classified according to 80th percentile into nega-
tive (< 80th percentile) versus positive (≥ 80th percentile).
Counting four structures or more, in five independent fields
of view, was used to classify tumors as positive, while less
than four were classified as negative. In addition, receiver
operating characteristic (ROC) curve analysis was per-
formed to confirm this cut off value for positivity. All slides
were viewed using a DP70 Olympus digital microscope
camera at 100×, 400× and 1000× (Mason Technologies,
UK). Images were captured with Olympus DP-Soft823
version 3.2 acquisition software. IHC scores were assessed
independently by two pathologists (S.E-M. & E.K., authors)
who were blinded to patient clinical data. Scoring was
consistent in 85 % of cases. Inconsistent scores were reas-
sessed by both S.E-M. and E.K. to assign final score.
Clinicopathologic data and outcome
The following clinical and histopathological data were
collected from medical charts and pathology reports:
age, gender, neoadjuvant therapy, follow up, tumor stage
and differentiation, vascular and neural invasion. The
clinical and histopathological data in both esophageal
adenocarcinoma patient groups are shown in Additional
file 1: Table S1.
Statistical analysis
Statistical analysis was carried out using SPSS software
(SPSS Inc., version 19; USA). Receiver operating charac-
teristic curve analysis was plotted using SPSS to determine
the cut off points for scoring. Chi-square test was used to
measure the association between qualitative variables.
Fisher exact test was used for 2 × 2 qualitative variables
where more than 25 % of the cells have an expected count
of less than 5. Kaplan-Meier survival curves were used to
assess impact of variables on overall survival. Where ap-
propriate, Cox regression was used to give an adjusted
hazard ratio and 95 % confidence interval of the effect of
the different risk factors for survival. The p-value was
considered statistically significant when it was less than
0.05. Patients form Cork and Dublin were analyzed separ-
ately and then together – as both patient cohorts achieved
significance with the same pattern.
Results
Validation of the LC3B autophagy marker
Prior to investigating expression of the autophagy marker
in cell lines or patient samples, we evaluated the specificity
of the Abgent LC3B antibody by western blotting with re-
combinant proteins. Western blot analysis of both LC3B
and LC3A recombinant proteins confirmed that the
Abgent LC3B antibody had a very weak affinity for LC3A
and predominantly reacts with LC3B (Fig. 1a). In contrast,
an MBL LC3 dual A/B reactive antibody detected both
isoforms of LC3 (Fig. 1b). This analysis confirmed high
specificity of the Abgent antibody for the LC3B isoform.
Previous work from this laboratory had identified drug
sensitive (OE21 and OE33) and resistant esophageal cell
lines (KYSE450 and OE19) that respond to therapeutic
agents by inducing apoptosis and autophagy respectively
[21]. Prior to investigating patient samples, we first vali-
dated immunohistochemical (IHC) detection of LC3B in
esophageal cancer cell lines, pre- and post-treatment with
the chemotherapeutic drug 5-fluorouracil (5-FU). Stand-
ard IHC staining shows the expression of LC3B in paraffin
embedded OE21 and KYSE450 cell lines (Additional file 2:
Figure S1A and B). OE21 (apoptotic competent) cells
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Fig. 1 Western blot analysis of human recombinant microtubule-associated proteins 1A/1B light chain 3A and 3B probed with either a the
Abgent anti-LC3 antibody (AP1802a), or b MBL anti-LC3A/B antibody. LC3 bands were quantified using the Odyssey Infrared Imaging System
(Li-Cor), and data presented as integrated intensities (n = 3). c Analysis of LC3B distribution in untreated OE21 and OE33 esophageal cancer cell
lines. Arrows indicate diffuse cytoplasmic LC3B expression (magnification 400×) (n = 6). d Analysis of LC3B distribution in untreated KYSE450 and
OE19 esophageal cell lines. Arrows indicate the presence of LC3B crescent or ring-like (upper panels) and globular (lower panels) structures in
KYSE450 and OE19 cells (magnification 1000×) (n = 6)
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show mild staining of LC3B before and after treatment
(Additional file 2: Figure S1A). In contrast, KYSE450 cells
show mild LC3B staining in pre-treatment sections,
whereas strong staining is evident following 5-FU treat-
ment (Additional file 2: Figure S1B). This corresponds to
immunofluorescence (IF) staining for LC3B in non-
embedded cell lines (Additional file 2: Figure S1C and D,
respectively).
Distribution of LC3B staining in untreated cells
Expression of LC3B was also evaluated by IHC in un-
treated drug sensitive (OE21 and OE33) and resistant
esophageal cell lines (KYSE450 and OE19) (Fig. 1c and d,
respectively). The LC3B staining detected in both cell lines
had a specific distribution, which was obvious at higher
magnification (400× and 1000×). Three distinct patterns
of LC3B expression were noted: (1) diffuse cytoplasmic
pattern, (2) crescent or ring-like structures and (3) large
globular structures. The first pattern; diffuse cytoplasmic
expression, which consists of fine granular structures dis-
tributed heterogeneously, was the predominant staining
pattern in untreated OE21 and OE33 (drug sensitive) cells
(Fig. 1c arrows). The other two patterns were found in
untreated KYSE450 and OE19 (drug resistant) cells. In ~
1/40 cells, a crescent shaped LC3B stained structure at the
nucleus or a perinuclear ring structure, was evident
(Fig. 1d upper panels, arrows). This appears to be formed
from a cluster of other smaller structures at the periphery
of the nucleus. In ~ 1/80 cells, a large globular structure
was present and this often occupied the majority of the
cell, marginalising the nucleus (Fig. 1d lower panels,
arrows).
Immunohistochemical analysis of LC3B expression in
esophageal adenocarcinoma patient tissue
The same three patterns of LC3B were also observed in
patient tumor samples (Fig. 2a-d): (i) cytoplasmic pattern,
(ii) crescent or ring-like structures and (iii) large globule
like structures. All patient samples (Group 1 and 2) were
scored and analyzed statistically, according to the follow-
ing LC3B staining distributions.
(i) Cytoplasmic
A cytoplasmic, finely granular or dot-like LC3B
staining pattern was observed in tumor sections
from both groups. In contrast to the diffuse
distribution observed in the cell lines, the staining
in patient samples was more polarized towards the
apical side of the cell (representative images shown
in Fig. 2a black arrows). Tumor sections were
considered positive if 50 % or more of the viable
tumor cells showed strong cytoplasmic staining. In
Group 1 (neoadjuvant-naïve), 43.3 % of tumor
sections showed positive LC3B cytoplasmic
staining. This distribution of staining was similar
in Group 2 (neoadjuvant therapy) where 52.1 % of
tumor sections were also positive.
(ii) Crescent or ring-like structure
The crescent or ring-like structure, composed of
multiple LC3B positive dots, was identified at the
periphery of the tumor cell nucleus in esophageal
adenocarcinoma tumor sections (representative
images shown in Fig. 2b and d black arrows). The
number of crescent or ring-like structures ranged
from 1 to 6 per section. The crescent or ring-like
structures in each tumor section were enumerated
and tumor samples were then classified into
groups accordingly. Four or more than four
crescent or ring-like structures per section was
classified as positive staining. In Group 1
(neoadjuvant-naïve), 34.6 % of tumor sections
were scored as positive, while the remaining
sections had less than four structures in the
examined section. In Group 2 (neoadjuvant
therapy), up to 72.9 % of tumor sections were
positive for crescent or ring-like structures.
(iii) Globular structure
A globular, densely stained structure was the third
LC3B staining pattern observed. These globular
structures varied in size, but usually they were
large, with some occupying most of the cytoplasm,
flattening the nuclei toward the periphery
(representative images shown in Fig. 2c black
arrows) or occasionally appearing to be within a
vacuole (Fig. 2d red arrow). The esophageal
adenocarcinoma patient tumor samples were then
grouped into positive and negative as above, with
four or more globular structures, in five
independent fields of view being classified as
positive staining. In patient Group 1
(neoadjuvant-naïve), 47.1 % of tumor samples
displayed positive staining of globular LC3B
structures, whereas in Group 2 (neoadjuvant
therapy), positive staining was observed in 77.1 %
of tumor samples.
Relationship between LC3B staining patterns and survival
Kaplan-Meier survival curves were plotted to assess
whether there is an association between LC3B staining
patterns and patient outcome. Patients from the two dif-
ferent sites, Cork (n = 50) and Dublin (n = 102), were
initially analyzed separately and then together for all
parameters, as both patient cohorts achieved similar sig-
nificance with the same assessment.
In Group 1 patients (neoadjuvant-naïve), positive cyto-
plasmic reactivity to LC3B was predictive of favourable
outcome, with > five-year survival, when compared with
negative cytoplasmic staining [(p < 0.001) (Fig. 3a)]. Group
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Fig. 2 (See legend on next page.)
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1 patients with negative LC3B crescent or ring-like struc-
tures had a better prognosis when compared to patients
with positive staining [(p = 0.02) (Fig. 3b)]. These staining
patterns were not predictive of prognosis in Group 2
patients (data not shown). A higher incidence of LC3B
positive globular structures, was highly predictive of poorer
outcome in both Group 1 [(p < 0.001) (Fig. 3c)] and Group
2 [(p < 0.001) (Fig. 3d)] patients. As this marker predicts five
year survival, regardless of whether the patient received
neoadjuvant therapy or not, Group 1 and Group 2 patients
can be pooled and collectively assessed (Fig. 3e). These
structures are highly indicative of outcome, irrespective of
treatment (p < 0.001).
Association between LC3B immunostaining patterns
The origin of the LC3B staining patterns is unknown and
it is possible that they are related or represent a functional
status of the tumor cell. We examined whether there was
any association between the cytoplasmic, crescent or ring-
like and globular LC3B staining patterns. In Group 2
patients (neoadjuvant therapy), there was no significant
association between the staining patterns. In contrast, in
Group 1 patients (neoadjuvant-naïve), the LC3B globular
structures had a direct relationship with crescent or ring-
like structures (Table 1). In patients who are positive for
LC3B globular structures, 63.3 % of these are also positive
for LC3B crescent or ring-like structures (p < 0.001) (see
also representative image Fig. 2d). The formation of these
structures may therefore be inter-related. Conversely,
there was an indirect relationship between LC3B globu-
lar structures and the cytoplasmic pattern of LC3B. Of
those patients who were negative for LC3B globular
structures, 63.6 % also had positive LC3B cytoplasmic
staining (p < 0.001). It is possible that the cytoplasmic
Fig. 3 Relationship between LC3B staining patterns and survival in patient Group 1 and Group 2. Kaplan-Meier survival curves for a cytoplasmic,
b crescent or ring-like structures and c globular LC3B staining patterns in Group 1 patients (neoadjuvant-naïve). d Kaplan-Meier survival curves for
LC3B staining patterns in Group 2 patients (neoadjuvant therapy). e Collective survival analysis of globular structures in patient Groups 1 and 2
(See figure on previous page.)
Fig. 2 LC3B expression patterns in esophageal adenocarcinoma tumor samples. All images to the left are at a magnification of 100×; the area within
the rectangle is shown to the right at the higher magnification of 400×. a Representative images of cytoplasmic expression of LC3B in esophageal
adenocarcinoma tumor cells (black arrows). b LC3B crescent or ring-like structures in tumor cells (black arrows). c LC3B globular structures
(black arrows). d LC3B crescent or ring-like structures (black arrows) and a globular structure which appears to be within a vacuole (red arrow)
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LC3B staining is present in a more normal/less stressed
state that does not tend to aggregate LC3B into larger
more defined structures. There was no significant associ-
ation between the cytoplasmic LC3B pattern and crescent
or ring-like structures. It is not known why these associa-
tions are only in Group 1 (neoadjuvant-naïve).
Multivariate analysis
We then examined the independent prognostic value of the
LC3B globular structure in both groups of esophageal
adenocarcinoma patients by multivariate cox regression
analysis. Multivariate analysis of parameters commonly
associated with poor prognosis, including tumor differenti-
ation, tumor staging, lymph node metastasis, vascular
invasion, neural invasion and LC3B globular structures is
shown in Table 2. In group 1 (neoadjuvant-naïve); the
presence of LC3B positive globular structures (HR = 6.086;
95 % confidence interval (CI) = 3.179–11.653; p < 0.001)
and vascular invasion (HR = 2.304; 95 % confidence inter-
val (CI) = 1.211–4.384; p = 0.011) were independent pre-
dictors of poor prognosis in all the variables examined. In
group 2 (neoadjuvant therapy); LC3B positive globular
structures was the only independent predictor of poor
prognosis in all the variables examined (HR = 9.136; 95 %
confidence interval (CI) = 2.115–39.462; p = 0.003).
Correlation between LC3B staining and histopathological
parameters
We also investigated whether LC3B staining was asso-
ciated with histopathological parameters and tumor
aggressiveness. We examined the relationship between
LC3B distribution patterns and tumor differentiation,
tumor staging and tumor metastasis in lymph nodes,
blood vessels or nerve fibres. An association with
Table 1 Relationship between distinct LC3B staining patterns in esophageal adenocarcinoma patient Group 1 (neoadjuvant-naïve).
Statistical analysis was carried out using chi-squared test (* p < 0. 05)
LC3B globular structures LC3B cytoplasmic
Negative Positive p–value Negative Positive p-value
LC3B crescent or ring-like structures
Negative 50(90.9 %) 18(36.7 %) <0.001* 36(61.0 %) 32(71.1 %) 0.3
Positive 5(9.1 %) 31(63.3 %) 23(39.0 %) 13(28.9 %)
LC3B cytoplasmic
Negative 20(36.4 %) 39(79.6 %) <0.001*
Positive 35(63.6 %) 10(20.4 %)
Table 2 Multivariate analysis of LC3B globular structures and other clinical pathological parameters that may have a potential role in
prognosis. The presence of LC3B globular structures has a strong independent prognostic value (p < 0.001)
Group 1 patients (neoadjuvant-naïve) Group 2 (neoadjuvant therapy)
Hazard ratio (95 % CI) p-value Hazard ratio (95 % CI) p-value
LC3B globular structures
Negative v’s Positive 6.086 (3.179–11.653) <0.001* 9.136 (2.115–39.462) 0.003*
Differentiation
Mild* 1(−) 0 1(−) 0
Moderate 0.667 (0.213–2.086) 0.487 0.000 0.976
Poor 0.898 (0.516–1.564) 0.704 0.677 (0.318–1.441) 0.311
Tumor staging
Stage I* 1(−) 0 1(−) 0
Stage II 0.627 (0.193–2.029) 0.435 2.877 (0.323–25.59) 0.343
Stage III-IV 0.858 (0.204–3.608) 0.835 5.043 (0.457–55.67) 0.187
Lymphatic mets
Negative v’s Positive 1.632 (0.504–5.288) 0.414 0.634 (0.196–2.055) 0.448
Vascular invasion
Negative v’s Positive 2.304 (1.211–4.384) 0.011* 0.559 (0.220–1.416) 0.220
Neural invasion
Negative v’s Positive 1.050 (0.548–2.009) 0.883 2.327 (0.876–6.181) 0.090
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histopathological parameters was found in Group 1
(neoadjuvant-naïve) patients, when LC3B staining pat-
terns were analyzed independently (Table 3). Negative
LC3B cytoplasmic reactivity is associated with esophageal
adenocarcinoma of moderate to poor differentiation
(p = 0.015). In addition, negative LC3B cytoplasmic
reactivity is associated with lymph node tumor metastasis
(p = 0.001), tumors with a late stage (III-IV) (p = 0.001)
and neural invasion (p = 0.004). On the other hand, posi-
tivity for LC3B globular structures is associated with
lymph node tumor metastasis (p = 0.013) and tumors with
a late stage (III-IV) (p = 0.003). In Group 2 (neoadjuvant
therapy), no association was detected between LC3B and
the aforementioned histopathological parameters (data
not shown). It is possible that the higher overall levels of
LC3B staining, as a consequence of neoadjuvant therapy in
Group 2 may obscure normal basal levels that may have
shown a relationship. This may also be due to a difference
in tumor biology following treatment.
LC3B expression in non-neoplastic esophageal squamous
epithelium
In Group 1 patients (neoadjuvant-naïve), no LC3B stain-
ing was detected in non-neoplastic esophageal squamous
epithelium. While Group 2 (neoadjuvant therapy) showed
low LC3B cytoplasmic reactivity. Crescent or ring-like and
globular LC3B structures were not detected in normal
esophageal squamous epithelium in either group (data not
shown).
Discussion
In this study, we have shown that specific staining patterns
of the autophagy marker (LC3B) are associated with pa-
tient outcome in esophageal adenocarcinoma.
The distribution patterns of LC3B were also relevant in
esophageal cell lines. Diffuse cytoplasmic LC3B staining
was detected in untreated, drug sensitive cell lines (OE21
and OE33) while the other two patterns; the crescent or
ring-like, and the globular patterns were present only in
drug resistant cells (KYSE450 and OE19). The LC3B ex-
pression patterns in patient samples corresponded with
the cell lines. In patients who did not receive therapy prior
to surgical resection, a positive cytoplasmic LC3B pattern
was statistically correlated with a more favourable out-
come, whereas the crescent or ring-like and the globular
patterns were associated with poor outcome. Importantly,
the globular pattern is associated with unfavourable prog-
nosis, regardless of whether the patient had neoadjuvant
therapy or not. Multivariate analysis found this marker to
be the strongest independent predictive variable in esopha-
geal cancer. This type of marker could be extremely useful,
as outcome could be determined in advance of a treatment
that is only effective in a sub-group of patients.
A relationship between the two patterns of LC3B stain-
ing, crescent or ring-like and the globular staining pattern
was also identified suggesting that they may originate from
the same process or be associated with the same phenotype.
Positive cytoplasmic LC3B staining was also associated with
a well-differentiated tumor, while negative cytoplasmic
Table 3 Relationship between LC3B staining patterns and histopathological parameters in Group 1 (neoadjuvant-naïve) esophageal
adenocarcinoma patients. Statistical analysis was carried out using chi-squared test (* p < 0. 05)
LC3B Cytoplasmic LC3B Globular structures
Negative Positive p–value Negative Positive p–value
Differentiation
Well 3(5.1 %) 8(17.8 %) 0.015* 8(14.5 %) 3(6.1 %) 0.292
Moderate 29(49.2 %) 27(60.0 %) 30(54.5 %) 26(53.1 %)
Poor 27(45.8 %) 10(22.2 %) 17(30.9 %) 20(40.8 %)
Tumor staging
Stage I 8(13.6 %) 9(20.0 %) 0.001* 12(21.8 %) 5(10.2 %) 0.003*
Stage II 9(15.3 %) 20(44.4 %) 21(38.2 %) 8(16.3 %)
Stage III-IV 42(71.2 %) 16(35.6 %) 22(40.0 %) 36(73.5 %)
Lymphatic mets
Negative 11(18.6 %) 23(51.1 %) 0.001* 24(43.6 %) 10(20.4 %) 0.013*
Positive 48(81.4 %) 22(48.9 %) 31(56.4 %) 39(79.6 %)
Vascular invasion
Negative 34(57.6 %) 29(64.4 %) 0.546 36(65.5 %) 27(55.1 %) 0.319
Positive 25(42.4 %) 16(35.6 %) 19(34.5 %) 22(44.9 %)
Neural invasion
Negative 36(61.0 %) 39(86.7 %) 0.004* 41(74.5 %) 34(69.4 %) 0.558
Positive 23(39.0 %) 6(13.3 %) 14(25.5 %) 15(30.6 %)
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expression was associated with late tumor stage and lymph
node metastasis. In addition, negative crescent/globular
structures were associated with absence of vascular inva-
sion. These results raise the possibility that the crescent/
globule patterns represent a new phenotype which supports
tumor progression. It is notable that these globule struc-
tures were only seen in a sub-population of the cells, in
both the cell lines and patient samples, the reason for this
is not known.
Studies of overall expression levels of LC3
Other studies have evaluated overall expression of LC3 in
cancer, with variable conclusions regarding significance. A
study of pancreatic tumors reported that high diffuse cyto-
plasmic LC3 reactivity at the periphery of the tumor
correlated with shorter disease free survival. A relationship
was identified between LC3 expression, tumor size and
tumor necrosis. The antibody used was anti-LC3A on tissue
sections from 71 cases [26]. LC3 expression was also exam-
ined in gastrointestinal cancer including esophageal squa-
mous carcinoma and no significant correlation between
LC3 expression and various clinicopathological parameters
or overall survival was identified [27]. In contrast, another
study of esophageal squamous cell carcinoma reported that
a high overall level of LC3, detected with a Novus rabbit
antibody (NB100-2220) is associated with shorter survival
[28]. In glioblastoma, high positive cytoplasmic staining of
LC3B was associated with an improved outcome in patients
[29]. A study of colorectal cancer, using an Abcam LC3B
polyclonal antibody, found negative LC3B expression and
absence of autophagy related proteins (Beclin 1 ATG5
LC3B) are associated with poor survival [30]. An analysis of
LC3A (Abcam EP1528Y) and LC3B (Abcam polyclonal) ex-
pression in breast cancer found an association with triple
negative and high grade tumors, but no overall association
with prognosis [31]. A meta-analysis of five LC3B expres-
sion studies (scoring high & low) in breast cancer reported
that a high expression of LC3B predicted a greater risk of
mortality [32]. While it is possible that these different con-
clusions reflect different tissue types, there is no uniformity
in the procedures and reagents (LC3A or LC3B antibodies
from various sources). The isoform selectivity of many of
these antibodies is currently unclear and the role of the five
LC3 isoforms (LC3Av1, LC3Av2, LC3B, LC3B2 and LC3C)
and related family members (GATE16 and GABARAP) in
autophagy has yet to be determined. Importantly, there are
divergent scoring methods and an absence of clear criteria
of positivity for the LC3 markers.
Studies reporting ‘stone like structures’ (SLS)
A number of studies from one group have reported LC3
data analogous to our data in other epithelial cancers.
They have reported distinct LC3A expression patterns in
breast [33], endometrial [34], pulmonary carcinoma [35],
cutaneous SCC [36], urothelial cell carcinoma (UCC) [37]
and colorectal cancer [38], using an anti-LC3A antibody
from Abgent (AP1805a). This antibody detects recom-
binant LC3A and not LC3B [39]. They detected LC3A
positive ‘stone like’ structures (SLS) that were strongly as-
sociated with tumor aggressiveness and poor prognosis.
These resemble the LC3B globular structures that we have
identified as a strong prognostic marker in esophageal
adenocarcinoma. They found that prognosis was largely
unaffected by the diffuse cytoplasmic pattern, except in
UCC where extensive cytoplasmic staining was associated
with muscle invasion [37]. In colorectal and breast cancer
a juxta-nuclear accumulation of LC3A protein was associ-
ated with lack of metastasis and predicted good prognosis.
In hepatocellular carcinoma, expression of LC3 at ad-
vanced tumor stages (but not early stages) was correlated
with longer survival. Diffuse cytoplasmic, juxta nuclear and
‘stone like’ structures were also examined and were not as-
sociated with prognosis in this study. This study employed
an LC3 antibody from Novus Biologicals [40] and they
found few patients with ‘stone like’ LC3 expression. Con-
versely, another group employing a rabbit polyclonal anti-
LC3A antibody (Abcam) reported a ‘stone like’ pattern of
LC3A expression to be an independent, highly prognostic
factor in hepatocellular carcinoma [41]. Another group also
identified LC3A SLS with the Abgent LC3A antibody
(AP1805a) in gastric cancer. A high number of SLS was as-
sociated with increased risk of recurrence after resection of
stages -III and lower overall survival rate for stage IV [25].
Thus, the use of antibodies directed to different iso-
forms of LC3 (LC3A - SLS studies and LC3B – our
group) enabled similar conclusions to be drawn by most
groups regarding the prognostic significance of LC3
globules/SLS in patient tissue. We currently do not
know if the Abgent LC3A antibody would have pro-
duced similar data to LC3B in our samples. A recent
study has reported that LC3Av1 and LC3B are the most
ubiquitously expressed isoforms in normal human tissue
and LC3Av1 is frequently silenced in cancer [42]. In-
deed, in OSCC the LC3Av1 gene is silenced in 66.7 %
(20/30) of cell lines analyzed. Therefore, if this was
reflected in esophageal adenocarcinoma and we had
used an antibody specific for LC3A rather than LC3B we
may have missed a relationship. It is also interesting that
this group reported silencing of LC3Av1 in 21 % of lung,
80 % of endometrial and 25 % of colorectal cancer cell
lines. However, LC3A SLS were detected in these
cancers by the Koukourakis team, suggesting that this
silencing may not happen in vivo, or that the LC3Av2
may compensate for loss of LC3Av1. It is also possible
that both LC3A and LC3B are incorporated into these
globular/SLS structures and that the LC3B antibody in
our study and the LC3A antibodies in the SLS studies
are detecting the same structures.
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The origin of these morphologically distinct LC3
stained structures is unknown. The more diffuse staining
in the cytoplasm may reflect soluble LC3B and basal
physiological autophagic activity. If these cancer cells
have a more ‘normal’ physiology – this may explain the
better prognosis. In contrast, the LC3A/B globular pat-
tern is an exclusive finding of aggressive malignant epi-
thelial cancers and may reflect an exaggerated or
aberrant form of autophagic activity. Further research is
needed to investigate the nature of this structure, which
is clearly linked to an aggressive tumor phenotype.
In conclusion, this is the first analysis of autophagy
markers in esophageal adenocarcinoma. In particular,
the LC3B globular structures identified in esophageal
adenocarcinoma patients are strongly associated with
patient outcome irrespective of treatment. The results of
this study are consistent with current published data on
other cancers and suggest that LC3B may be a unique
marker in predicting prognosis in esophageal cancer.
Further multi-centre retrospective and prospective stud-
ies, would be encouraged to further validate the prog-
nostic significance of this marker.
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